US Patent

US10842801 — Optimizing mifepristone absorption

Method of Use · Assigned to Corcept Therapeutics Inc · Expires 2032-11-15 · 6y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method of increasing mifepristone absorption into the blood by administering it with meals.

USPTO Abstract

The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders.

Drugs covered by this patent

Mifeprex (MIFEPRISTONE) · Corcept Therap

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1643`	—	Mifeprex

Patent Metadata

Patent number: US10842801
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-15
Drug substance claim: No
Drug product claim: No
Assignee: Corcept Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.